PSA Annual Report FY 2024-25: Stronger, Bigger, Better

26 November 2025 

 

The Pharmaceutical Society of Australia (PSA) has released its 2024/25 Annual Report, establishing a year of growth and delivery, with PSA identified as the home of more pharmacists than ever before.  

 

At the Annual General Meeting held on Monday 24 November, the PSA reported a total surplus of $2.167 million during the Financial Year 2024-2025, with recognition of growth in several key areas including membership numbers, member support, training and education products and services, policy submissions, partnerships and general investment income.   

 

The PSA continued to grow as the professional home for all pharmacists. With substantial membership growth approaching 20,000 by the end of the FY24-25 reporting period, this 10% increase is the highest membership growth PSA has achieved as a national organisation since its inception. This membership growth has also continued in Q1 of FY26. 

 

During the preceding year, the PSA Board made strategic decisions to invest in the development of new education products, including full scope prescribing and clinical training, MMR and ACOP credentials, and new specialty communities. The PSA is committed to expanding the scope of practice and workforce capability, thereby improving health outcomes for Australians. 

 

The PSA’s other key achievements also included growth in the PSA Foundation’s asset value and activities, the launch of the Hospital Pharmacy Community of Specialty Interest, the inaugural PSA General Practice Pharmacist Symposium, and the launch of the MMR and ACOP credentials. 

 

The organisation advanced key priorities under Pharmacists in 2030, empowering pharmacists to practise to their full potential, and shaping emerging career pathways.  

 

Reflecting on the fiscal year, PSA National President and Board Chair, Associate Professor Fei Sim FPS, said she was incredibly proud of the progress made and encouraged all pharmacists to come together to transform the profession. 

 

“Our strength lies in the collective expertise, passion, and dedication of our members. PSA is owned and led by our members. PSA will continue to focus on delivering member value and supporting our workforce as our scope evolves,” Associate Professor Sim said. 

 

“The strategy of our PSA Board is clear – we are here to support the profession to deliver improved quality use of medicines and access to care for all Australians. This fundamental principle then informed all strategic decisions of the Board – from investing in the development of new education products and member services, to the PSA Foundation’s activities and policy positions, to the acquisition of the College. 

 

“I call on you, our members, to continue supporting the PSA and stay involved. Together, we can strengthen our influence, share our knowledge, and shape the future of our beloved profession.” 

 

PSA CEO Adjunct Associate Professor Steve Morris said this year was about delivery, turning vision into action through partnerships, evidence, and innovation while maintaining strong financial stewardship. 

 

“Our teams have been agile, delivering new products while continuing to serve PSA’s members and stakeholders,” Associate Professor Morris said. 

 

“Every one of our initiatives helps PSA to build a stronger profession and leads the development of the pharmacy workforce to support the swelling healthcare needs of Australia’s ageing population. 

 

“We have maintained strong fiscal control, helping us deliver one of the organisation’s strongest financial results in some years. This result is particularly remarkable considering membership fees have not increased since 2018.” 

 

The PSA Annual Report for 2024-25 is available for download here.

 

Media contact: Leah Jacobsen

M: 0480 099 798  E: leah.jacobsen@psa.org.au 

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.